3 results about "Epirubicin" patented technology

Provided is a novel crystallization method for epirubicin hydrochloride. Provided is a production method for crystals of epirubicin hydrochloride that includes (a) a step for obtaining a mixture that includes epirubicin hydrochloride, two alcohols, and water and (b) a step for adding an ether to the mixture obtained at step (a) and crystallizing the epirubicin hydrochloride. Also provided are novel crystals of epirubicin hydrochloride.

This invention provides a novel crystallization method for epirubicin hydrochloride. [Solution] A method for producing epirubicin hydrochloride crystals is provided, comprising the steps of (a) obtaining a mixture containing epirubicin hydrochloride, two types of alcohol, and water, and (b) adding ether to the mixture obtained in step (a) to crystallize the epirubicin hydrochloride. A novel crystal of epirubicin hydrochloride is also provided.

(3R, 4S)-3-(4-hydroxy-3,5-dimethoxyphenyl)-4-(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H- chromen-7-ol (TRX-E-002-1) for use in a method of treatment for a hematological cancer being acute myeloid leukemia or multiple myeloma in a subject in need thereof, the method comprising administering to the subject an effective amount of TRX-E-002-1. The method may further comprise administering to the subject an effective amount of a second compound selected from the group consisting of (i) a BCL-2 inhibitor such as venetoclax, navitoclax or obatoclax, (ii) a deoxycytidine analogue chemotherapeutic such as cytarabine or gemcitabine, (iii) a hypomethylating agent such as azacitidine or decitabine, (iv) an anthracycline chemotherapeutic such as daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin or mitoxantrone, (v) a proteasome inhibitor such as carfilzomib, bortezomib, and ixazomib, (vi) an immunomodulatory drug such as pomalidomide, lenalidomide, and thalidomide and(vii) a corticosteroid drug such as dexamethasone or prednisone, and (viii) an alkylator such as bendamustine, cyclophosphamide, melphalan, and melflufen. Corresponding combination pharmaceutical compositions.